Tagged with CDMO

Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…

Turkey Arven Pharmaceuticals is the Turkish R&D-based company behind the first biosimilar drug developed and manufactured from cell to final product in the country, and the first patented and produced dry powder inhaler in Turkey. Its founder and president, Zafer Toksöz, explains the company’s pioneering journey and the circumstances that have…

APAC Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand for the research, development, and manufacturing of therapies and vaccines against COVID-19. Van Parys also outlines the opportunities and challenges…

APAC Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand for the research, development, and manufacturing of therapies and vaccines against COVID-19. Van Parys also outlines the opportunities and challenges…

Switzerland Swiss-based Lonza has consolidated as a titan in the CDMO industry with annual revenues of around CHF 5.9bn for 2020. Its president for the Biologics and Cell & Gene divisions, Jean-Christophe Hyvert, comments on the restructuring of the company, why the divesture of the specialty ingredients division makes sense in…

France Fresh from a management buyout and the establishment of Skyepharma as an independent company, Managing Director David Lescuyer charts the fully integrated French CDMO’s startling growth trajectory over the past five years and outlines how the firm is well positioned for further growth. Lescuyer also highlights some of the key…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Singapore Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Switzerland The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership with Moderna, and his view on the new processes and technology shaping the industry.   A CDMO does not really…